Table 5.
Multi-country: risk of fracture in current TZD users compared with other antidiabetic users, by type of fracture and sex.
| Multi-country |
|||||||
|---|---|---|---|---|---|---|---|
| Fracture, n= | Age-sexadj HR | CI | Fully adj HR (a) | CI | |||
| Control (other AD drug user) | 32,244 | 1 | 1 | ||||
| CURRENT TZD USER | |||||||
| Any fracture | 1,644 | 1.25 | 1.18 | 1.31 | 1.27 | 1.21 | 1.34 |
| Male | 538 | 1.01 | 0.92 | 1.10 | 1.05 | 0.96 | 1.14 |
| Female | 1,106 | 1.42 | 1.33 | 1.51 | 1.44 | 1.35 | 1.53 |
| Osteoporotic fracture | 884 | 1.20 | 1.12 | 1.29 | 1.23 | 1.14 | 1.32 |
| Male | 248 | 0.95 | 0.83 | 1.08 | 0.99 | 0.87 | 1.13 |
| Female | 636 | 1.35 | 1.25 | 1.47 | 1.37 | 1.26 | 1.49 |
| Hip | 214 | 0.91 | 0.79 | 1.05 | 0.93 | 0.81 | 1.06 |
| Vertebral | 69 | 1.08 | 0.84 | 1.39 | 1.12 | 0.87 | 1.44 |
| Radius/ulna | 253 | 1.47 | 1.29 | 1.68 | 1.50 | 1.31 | 1.71 |
| Femur | 33 | 1.11 | 0.78 | 1.59 | 1.15 | 0.80 | 1.65 |
| Pelvis | 42 | 1.30 | 0.94 | 1.79 | 1.32 | 0.96 | 1.82 |
| Humerus | 215 | 1.48 | 1.28 | 1.71 | 1.53 | 1.32 | 1.77 |
| Ribs | 72 | 1.06 | 0.83 | 1.35 | 1.11 | 0.87 | 1.43 |
| Patella fracture | 17 | 1.09 | 0.65 | 1.80 | 1.13 | 0.68 | 1.87 |
| Tibia/fibula fracture | 119 | 1.56 | 1.28 | 1.89 | 1.60 | 1.32 | 1.95 |
| Ankle fracture | 176 | 1.53 | 1.30 | 1.80 | 1.57 | 1.34 | 1.85 |
| Foot fracture | 122 | 1.24 | 1.02 | 1.51 | 1.32 | 1.08 | 1.60 |
(a) Adjusted for age, sex, current use of biguanides, sulfonylureas, insulin, or other antidiabetics (including DPP-4 inhibitors, glinides, GLP-1 analogs, and alpha glucosidase inhibitors).